Jan, 22 2019 17:54 JST

Source: Eisai

Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time

Highest Ranked Japanese Company

TOKYO, Jan, 22 2019 - (JCN Newswire) - Eisai Co., Ltd. has been listed in the 2019 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's fourth inclusion on the list. Ranked 73rd, Eisai was the highest ranking Japanese company among the eight Japanese companies listed in the Global 100.

The Global 100 evaluates the sustainability of approximately 7,500 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year at the World Economic Forum in Davos. The Global 100 is based on up to 21 key performance indicators covering financial management, clean revenue, supplier performance, employee management and resource management, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this corporate philosophy, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech, HealthCare

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease
March 22 2019 10:37 JST
 
Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases
March 22 2019 10:23 JST
 
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
March 21 2019 23:25 JST
 
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
March 12 2019 07:43 JST
 
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
March 07 2019 11:30 JST
 
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan
February 27 2019 10:52 JST
 
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
February 21 2019 13:50 JST
 
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy
February 13 2019 08:29 JST
 
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study
February 04 2019 11:57 JST
 
Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa
January 30 2019 15:22 JST
 
More Press release >>

Latest Press Release


More Latest Release >>